Posted on 3 月 12, 20243/12/24
Evolving Dynamics in Oncology: Considerations for Overcoming Commercialization Challenges and Driving Greater Impact
Posted on 2 月 19, 20242/19/24
Navigating Successful Partnerships in the Pharmaceutical Industry: Insights from Shorla Oncology CEO Sharon Cunningham
Posted on 7 月 18, 20237/18/23
Specialty Pharmacies are Ready for the Biosimilar Boom. Are you?
Posted on 7 月 13, 20237/13/23
Overcoming the Commercialization Challenges of Personalized Cancer Immunotherapies
Posted on 6 月 16, 20236/16/23
Digital Guide to Commercializing Complex Therapeutics
Posted on 5 月 31, 20235/31/23
Patient-centric Approach to Clinical Trial Support Leveraging Medical Information Services
Posted on 4 月 27, 20234/27/23
The Necessity of Mapping the Tumor Journey for Oncology Marketers
Posted on 4 月 17, 20234/17/23
What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry
Posted on 3 月 13, 20233/13/23
Accelerated Approval Pathways: Manufacturers Left to Grapple With Risk Versus Reward
Posted on 2 月 22, 20232/22/23